| Autor: |
Grant-Klein RJ; Merck & Co., Inc., Kenilworth, New Jersey., Antonello J; Merck & Co., Inc., Kenilworth, New Jersey., Nichols R; Crozet BioPharma, Devens, Massachusetts., Dubey S; Merck & Co., Inc., Kenilworth, New Jersey., Simon J; Merck & Co., Inc., Kenilworth, New Jersey. |
| Abstrakt: |
rVSVΔG-ZEBOV-GP vaccine is a live recombinant (r) vesicular stomatitis virus (VSV), where the VSV G protein is replaced with the Zaire Ebola virus (ZEBOV) glycoprotein (GP). For vaccine immunogenicity testing, clinical trial sera collected during an active ZEBOV outbreak underwent gamma irradiation (GI) before testing in biosafety level 2 laboratories to inactivate possible wild-type ZEBOV. Before irradiating pivotal trial samples, two independent studies evaluated the impact of GI (50 kGy) on binding ZEBOV-GP (ELISA) antibodies against rVSVΔG-ZEBOV-GP, using sera from a North American phase 1 study. Gamma irradiation was associated with slightly higher antibody concentrations in pre-vaccination samples and slightly lower concentrations postvaccination. Results indicate that GI is a viable method for treating samples from regions where filoviruses are endemic, with minor effects on antibody titers. The impact of GI on immunogenicity analyses should be considered when interpreting data from irradiated specimens. |
